Myelin-Mediated Inhibition of Axonal Regeneration: Past, Present, and Future
Pioneering studies conducted in the 1980’s laid the foundation for the hypothesis that axonal regeneration is limited by CNS myelin, and the identification of myelin-associated glycoprotein (MAG), Nogo, and oligodendrocyte myelin glycoprotein (OMgp) as inhibitors of neurite outgrowth firmly establis...
Saved in:
Superior document: | Frontiers Research Topics |
---|---|
: | |
Year of Publication: | 2017 |
Language: | English |
Series: | Frontiers Research Topics
|
Physical Description: | 1 electronic resource (116 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993546335504498 |
---|---|
ctrlnum |
(CKB)4100000000883853 (oapen)https://directory.doabooks.org/handle/20.500.12854/54180 (EXLCZ)994100000000883853 |
collection |
bib_alma |
record_format |
marc |
spelling |
Wilfredo Mellado auth Myelin-Mediated Inhibition of Axonal Regeneration: Past, Present, and Future Myelin-Mediated Inhibition of Axonal Regeneration Frontiers Media SA 2017 1 electronic resource (116 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Frontiers Research Topics Pioneering studies conducted in the 1980’s laid the foundation for the hypothesis that axonal regeneration is limited by CNS myelin, and the identification of myelin-associated glycoprotein (MAG), Nogo, and oligodendrocyte myelin glycoprotein (OMgp) as inhibitors of neurite outgrowth firmly established myelin as a key factor in regenerative failure. Mechanistically, it has been shown that MAG, Nogo, and OMgp mediate inhibition by binding to either Nogo receptor (NgR) or paired immunoglobulin receptor B (PirB), and initiating a signaling cascade that culminates in the activation of RhoA. Since the discovery of these proteins, there has been tremendous interest in identifying compounds and molecular mechanisms that are capable of overcoming myelin-mediated inhibition. Many studies have focused on pharmacological antagonism of receptors and signaling intermediates, while others have sought to identify and enhance endogenous pro-regenerative pathways. The most notable example of the latter is the conditioning lesion effect, which led to the discovery of cyclic AMP’s ability to overcome inhibition by MAG and myelin. Many of the agents tested in these studies have been shown to promote axonal regeneration in vivo, and this research topic allows researchers to share information about new treatments that have been developed in both academia and industry. As we look toward the future, it is becoming increasingly clear that reversal of myelin-mediated inhibition alone will not be sufficient to produce functional recovery from spinal cord injury, and that other factors, such as astroglial scarring, the expression of chondroitin sulfate proteoglycans, neuronal cell death, and lack of neurotrophic support, must also be taken into consideration. Combinatorial approaches therefore hold a great deal of promise, and we hope to initiate a dialogue on how stem cell transplantation, chondroitinase ABC, gene therapy, growth-promoting agents, and other methods can be combined to optimize functional recovery. We introduce this topic in honor of the life and work of Dr. Marie T. Filbin (1955-2014). Through these articles, we highlight past achievements in the field, novel findings, unanswered questions and innovative ideas that we hope will lead to new advances in axonal regeneration. English MAG Omgp axonal regeneration myelin-associated inhibitors CNS regeneration Nogo cAMP 2-88945-206-9 Sari Hannila auth |
language |
English |
format |
eBook |
author |
Wilfredo Mellado |
spellingShingle |
Wilfredo Mellado Myelin-Mediated Inhibition of Axonal Regeneration: Past, Present, and Future Frontiers Research Topics |
author_facet |
Wilfredo Mellado Sari Hannila |
author_variant |
w m wm |
author2 |
Sari Hannila |
author2_variant |
s h sh |
author_sort |
Wilfredo Mellado |
title |
Myelin-Mediated Inhibition of Axonal Regeneration: Past, Present, and Future |
title_full |
Myelin-Mediated Inhibition of Axonal Regeneration: Past, Present, and Future |
title_fullStr |
Myelin-Mediated Inhibition of Axonal Regeneration: Past, Present, and Future |
title_full_unstemmed |
Myelin-Mediated Inhibition of Axonal Regeneration: Past, Present, and Future |
title_auth |
Myelin-Mediated Inhibition of Axonal Regeneration: Past, Present, and Future |
title_alt |
Myelin-Mediated Inhibition of Axonal Regeneration |
title_new |
Myelin-Mediated Inhibition of Axonal Regeneration: Past, Present, and Future |
title_sort |
myelin-mediated inhibition of axonal regeneration: past, present, and future |
series |
Frontiers Research Topics |
series2 |
Frontiers Research Topics |
publisher |
Frontiers Media SA |
publishDate |
2017 |
physical |
1 electronic resource (116 p.) |
isbn |
2-88945-206-9 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT wilfredomellado myelinmediatedinhibitionofaxonalregenerationpastpresentandfuture AT sarihannila myelinmediatedinhibitionofaxonalregenerationpastpresentandfuture AT wilfredomellado myelinmediatedinhibitionofaxonalregeneration AT sarihannila myelinmediatedinhibitionofaxonalregeneration |
status_str |
n |
ids_txt_mv |
(CKB)4100000000883853 (oapen)https://directory.doabooks.org/handle/20.500.12854/54180 (EXLCZ)994100000000883853 |
carrierType_str_mv |
cr |
hierarchy_parent_title |
Frontiers Research Topics |
is_hierarchy_title |
Myelin-Mediated Inhibition of Axonal Regeneration: Past, Present, and Future |
container_title |
Frontiers Research Topics |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1796649072024616960 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03426nam-a2200373z--4500</leader><controlfield tag="001">993546335504498</controlfield><controlfield tag="005">20231214133349.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2017 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4100000000883853</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/54180</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994100000000883853</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Wilfredo Mellado</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Myelin-Mediated Inhibition of Axonal Regeneration: Past, Present, and Future</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Myelin-Mediated Inhibition of Axonal Regeneration</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (116 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers Research Topics</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Pioneering studies conducted in the 1980’s laid the foundation for the hypothesis that axonal regeneration is limited by CNS myelin, and the identification of myelin-associated glycoprotein (MAG), Nogo, and oligodendrocyte myelin glycoprotein (OMgp) as inhibitors of neurite outgrowth firmly established myelin as a key factor in regenerative failure. Mechanistically, it has been shown that MAG, Nogo, and OMgp mediate inhibition by binding to either Nogo receptor (NgR) or paired immunoglobulin receptor B (PirB), and initiating a signaling cascade that culminates in the activation of RhoA. Since the discovery of these proteins, there has been tremendous interest in identifying compounds and molecular mechanisms that are capable of overcoming myelin-mediated inhibition. Many studies have focused on pharmacological antagonism of receptors and signaling intermediates, while others have sought to identify and enhance endogenous pro-regenerative pathways. The most notable example of the latter is the conditioning lesion effect, which led to the discovery of cyclic AMP’s ability to overcome inhibition by MAG and myelin. Many of the agents tested in these studies have been shown to promote axonal regeneration in vivo, and this research topic allows researchers to share information about new treatments that have been developed in both academia and industry. As we look toward the future, it is becoming increasingly clear that reversal of myelin-mediated inhibition alone will not be sufficient to produce functional recovery from spinal cord injury, and that other factors, such as astroglial scarring, the expression of chondroitin sulfate proteoglycans, neuronal cell death, and lack of neurotrophic support, must also be taken into consideration. Combinatorial approaches therefore hold a great deal of promise, and we hope to initiate a dialogue on how stem cell transplantation, chondroitinase ABC, gene therapy, growth-promoting agents, and other methods can be combined to optimize functional recovery. We introduce this topic in honor of the life and work of Dr. Marie T. Filbin (1955-2014). Through these articles, we highlight past achievements in the field, novel findings, unanswered questions and innovative ideas that we hope will lead to new advances in axonal regeneration.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">MAG</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Omgp</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">axonal regeneration</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">myelin-associated inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CNS regeneration</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Nogo</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cAMP</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88945-206-9</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sari Hannila</subfield><subfield code="4">auth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:51:38 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2017-11-11 16:18:22 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338233210004498&Force_direct=true</subfield><subfield code="Z">5338233210004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338233210004498</subfield></datafield></record></collection> |